The data on melanoma CAFs are still emerging, especially relative to breast cancer, and existing data often reflect the push to address treatment resistance to checkpoint blockade therapy and drugs targeting melanoma specific mutants such as BRAF. This evidence concerns the gene BRAF and breast carcinoma.